HMPL 415S1
Alternative Names: HMPL-415; HMPL-415S1Latest Information Update: 03 Jun 2024
At a glance
- Originator HUTCHMED
- Class Antineoplastics
- Mechanism of Action SH2 domain-containing protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 Dec 2023 Hutchmed has patents pending for methods of treating cancers, Noonan Syndrome and LEOPARD Syndrome in China, USA, Europe and Japan (SEC file 2023- HUTCHMED)
- 11 Oct 2023 Pharmacodynamics and safety data from a preclinical studies in Solid tumors presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 01 Jul 2023 Phase-I trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in China (PO) (NCT05886374)